Supernus Pharma Cash Flow - Quarterly (NASDAQ:SUPN)

Add to My Stocks
$47.9 $1 (2.13%) SUPN stock closing price Sep 19, 2018 (Closing)

For analyzing any company like Supernus Pharma from an investment perspective, its important to check the cash flow statement. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Supernus Pharma profits and Supernus Pharma debt. Supernus Pharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Supernus Pharma had cash and cash equivalents of $100.3M at the beginning of the quarter and $35.21M at quarter end for 2018 Q2. Supernus Pharma had an inflow of $33.69M from operating activities, $374.36M inflow due to financing activities, and $-473.15M outflow due to investing activities till 2018 Q2.

View and download details of Supernus Pharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
57.09M26.35M57.28M43.62M27.66M10.29M91.22M76.9M15M4.98M
Depreciation Depletion Amortization Cash-Flow5.96M2.4M7.61M6.51M2.08M-2.91M2.24M1.11M-
Net Increase (Decrease) in Assets Liabilities-33.79M-2.54M23.71M10.96M-4.84M-3.3M8.44M--6.02M-10.35M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.43M-26.02M17.2M14.4M5.62M-35.77M-37.79M3.53M1.79M
Net Cash from (used by) Operating Activities
33.69M27.13M114.64M78.3M39.3M13.35M66.81M41.87M13.63M-3.14M
Increase (Decrease) in Prop Plant And Equipment-0.56M-0.25M-2.02M-1.27M-0.85M-0.3M-1.6M-1.3M-0.9M-0.27M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-472.19M-50.41M-73.23M-55.88M-36.04M-17.05M-15.54M-8.79M-8.03M-10.58M
Other Cash Inflow (Outflow) from Investment Activities-0.4M-0.34M-11.15M-10.13M-9.22M-3.4M-18.82M-12.22M-3.68M-0.43M
Net Cash from (used by) Investment Activities
-473.15M-51.01M-86.41M-67.28M-46.12M-20.76M-35.96M-22.32M-12.62M-11.3M
Issuance (Purchase) of Equity Shares9.5M2.85M5.68M4.51M2.16M-2.05M1.25M--
Issuance (Repayment) of Debt Securities402.5M402.5M--------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-37.64M-37.64M--------
Net Cash from (used by) Financing Activities
374.36M367.71M5.68M4.51M2.16M-2.05M1.25M--
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
-65.1M343.83M33.9M15.52M-4.66M-6.79M32.9M20.8M2M-14.32M
Cash & Equivalents at Beginning of Year100.3M66.39M33.49M36.39M32.98M40.3M48.54M23.74M31.4M-
Cash & Equivalents at Year End35.21M444.14M100.3M81.92M61.73M59.59M66.39M54.3M36.15M19.83M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Supernus Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Supernus Pharma stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Supernus Pharma had a Net Change in Cash and Cash Equivalents of $-65.1M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Supernus Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Supernus Pharma increased its cash from operating activities to $33.69M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-473.15M for SUPN till last quarter 2018 Q2 report.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Supernus Pharma earned $374.36M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Supernus Pharma Cash Flow

FCF margin
0.06

Quarterly Cash Flow Statements For Supernus Pharmaceuticals Inc Peers

Akorn cash flow, Catalent cash flow, Mallinckrodt cash flow, Dr. Reddy's Laboratories cash flow, Relypsa cash flow